Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

International Immunopharmacology

Volumn 62, Issue , 2018, Pages 29-39

  Hargadon, Kristian M ^a   Johnson, Coleman E ^a   Williams, Corey J ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

Cancer immunotherapy; CTLA 4; Immune checkpoint blockade; PD 1; PD L1

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85049351361     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2018.06.001     Document Type: Review

References (100)

1. Dighe, A.S., Richards, E., Old, L.J., Schreiber, R.D., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994), 447–456.
2. Levitsky, H.I., Lazenby, A., Hayashi, R.J., Pardoll, D.M., In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179 (1994), 1215–1224.
3. van den Broek, M.E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W.K., Melief, C.J., Zinkernagel, R.M., Hengartner, H., Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184 (1996), 1781–1790.
4. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., Schreiber, R.D., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7556–7561.
5. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H., The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998), 2357–2368.
6. Smyth, M.J., Thia, K.Y., Street, S.E., MacGregor, D., Godfrey, D.I., Trapani, J.A., Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192 (2000), 755–760.
7. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
8. Smith, J.L., Stehlin, J.S., Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18 (1965), 1399–1415.
9. Halliday, G.M., Patel, A., Hunt, M.J., Tefany, F.J., Barnetson, R.S.C., Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J. Surg. 19 (1995), 352–358.
10. Saleh, F.H., Crotty, K.A., Hersey, P., Menzies, S.W., Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int. J. Cancer 94 (2001), 551–557.
11. Mortarini, R., Piris, A., Maurichi, A., Molla, A., Bersani, I., Bono, A., Bartoli, C., Santinami, M., Lombardo, C., Ravagnani, F., Cascinelli, N., Parmiani, G., Anichini, A., Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 63 (2003), 2535–2545.
12. Deng, L., Zhang, H., Luan, Y., Zhang, J., Xing, Q., Dong, S., Wu, X., Liu, M., Wang, S., Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 16 (2010), 4105–4112.
13. Severson, J.J., Serracino, H.S., Mateescu, V., Raeburn, C.D., McIntyre, R.C., Sams, S.B., Haugen, B.R., French, J.D., PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer. Cancer Immunol. Res. 3 (2015), 620–630.
14. Shahinian, A., Pfeffer, K., Lee, K.P., Kündig, T.M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P.S., Thompson, C.B., Mak, T.W., Differential T cell costimulatory requirements in CD28-deficient mice. Science 261 (1993), 609–612.
15. Joffre, O., a Nolte, M., Spörri, R., Reis e Sousa, C., Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227 (2009), 234–247.
16. Chen, L., Flies, D.B., Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13 (2013), 227–242.
17. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., Bluestone, J.A., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994), 405–413.
18. Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., Baker, J., Jeffery, L.E., Kaur, S., Briggs, Z., Hou, T.Z., Futter, C.E., Anderson, G., Walker, L.S.K., Sansom, D.M., Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332 (2011), 600–603.
19. Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (1995), 459–465.
20. Greenwald, R.J., Boussiotis, V.A., Lorsbach, R.B., Abbas, A.K., Sharpe, A.H., CTLA-4 regulates induction of anergy in vivo. Immunity 14 (2001), 145–155.
21. Krummel, M.F., Allison, J.P., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183 (1996), 2533–2540.
22. Chambers, C.A., Sullivan, T.J., Truong, T., Allison, J.P., Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28 (1998), 3137–3143.
23. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., Sakaguchi, S., CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 (2008), 271–275.
24. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. J. Exp. Med. 206 (2009), 1717–1725.
25. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.e17.
26. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., Akerley, W., van den Eertwegh, A.J.M., Lutzky, J., Lorigan, P., Vaubel, J.M., Linette, G.P., Hogg, D., Ottensmeier, C.H., Lebbé, C., Peschel, C., Quirt, I., Clark, J.I., Wolchok, J.D., Weber, J.S., Tian, J., Yellin, M.J., Nichol, G.M., Hoos, A., Urba, W.J., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
27. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M., Wolchok, J.D., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33 (2015), 1889–1894.
28. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W.H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T.T., Humphrey, R., Hoos, A., Wolchok, J.D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364 (2011), 2517–2526.
29. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
30. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999), 141–151.
31. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Fouser, L., Carter, L., Ling, V., Bowman, M.R., Carreno, B.M., Collins, M., Wood, C.R., Honjo, T., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000), 1027–1034.
32. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., Greenfield, E.A., Bourque, K., Boussiotis, V.A., Carter, L.L., Carreno, B.M., Malenkovich, N., Nishimura, H., Okazaki, T., Honjo, T., Sharpe, A.H., Freeman, G.J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001), 261–268.
33. Goldberg, M.V., Maris, C.H., Hipkiss, E.L., Flies, A.S., Zhen, L., Tuder, R.M., Grosso, J.F., Harris, T.J., Getnet, D., Whartenby, K.A., Brockstedt, D.G., Dubensky, T.W., Chen, L., Pardoll, D.M., Drake, C.G., Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110 (2007), 186–192.
34. Francisco, L.M., Salinas, V.H., Brown, K.E., Vanguri, V.K., Freeman, G.J., Kuchroo, V.K., Sharpe, A.H., PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206 (2009), 3015–3029.
35. Blank, C., Brown, I., Peterson, A.C., Spiotto, M., Iwai, Y., Honjo, T., Gajewski, T.F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64 (2004), 1140–1145.
36. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., Honjo, T., PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198 (2003), 39–50.
37. Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., Ahmed, R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
38. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., Rosenberg, S.A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
39. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., Lennon, V.A., Celis, E., Chen, L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
40. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Lao, C.D., Linette, G.P., Thomas, L., Lorigan, P., Grossmann, K.F., Hassel, J.C., Maio, M., Sznol, M., Ascierto, P.A., Mohr, P., Chmielowski, B., Bryce, A., Svane, I.M., Grob, J.J., Krackhardt, A.M., Horak, C., Lambert, A., Yang, A.S., Larkin, J., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16 (2015), 375–384.
41. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Hernberg, M.M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I.M., Atkinson, V., Ascierto, P.A., Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
42. Weber, J., Mandala, M., Del Vecchio, M., Gogas, H.J., Arance, A.M., Cowey, C.L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J.J., Butler, M.O., Middleton, M.R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R.R., Smylie, M., Meyer, N., Mortier, L., Atkins, M.B., Long, G.V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T.M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., Ascierto, P.A., CheckMate 238 collaborators, adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377 (2017), 1824–1835.
43. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
44. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crinò, L., Blumenschein, G.R., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
45. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., Castellano, D., Choueiri, T.K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T.C., Ueda, T., Tomita, Y., Schutz, F.A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J.S., Xu, L.A., Waxman, I.M., Sharma, P., 025 Investigators, CheckMate, Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
46. Ferris, R.L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., Worden, F., Saba, N.F., Iglesias Docampo, L.C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W.J., Kopit, J., Shaw, J.W., Gillison, M.L., Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375 (2016), 1856–1867.
47. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E.R., Vaena, D., Grimm, M.-O., Bracarda, S., Arranz, J.Á., Pal, S., Ohyama, C., Saci, A., Qu, X., Lambert, A., Krishnan, S., Azrilevich, A., Galsky, M.D., Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18 (2017), 312–322.
48. El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T.H., Meyer, T., Kang, Y.-K., Yeo, W., Chopra, A., Anderson, J., dela Cruz, C., Lang, L., Neely, J., Tang, H., Dastani, H.B., Melero, I., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.
49. Overman, M.J., McDermott, R., Leach, J.L., Lonardi, S., Lenz, H.J., Morse, M.A., Desai, J., Hill, A., Axelson, M., Moss, R.A., Goldberg, M.V., Cao, Z.A., Ledeine, J.M., Maglinte, G.A., Kopetz, S., André, T., Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18 (2017), 1182–1191.
50. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A., Armand, P., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372 (2015), 311–319.
51. Younes, A., Santoro, A., Shipp, M., Zinzani, P.L., Timmerman, J.M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J.B., Collins, G., Savage, K.J., Trneny, M., Kato, K., Farsaci, B., Parker, S.M., Rodig, S., Roemer, M.G.M., Ligon, A.H., Engert, A., Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17 (2016), 1283–1294.
52. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., Cranmer, L.D., Blank, C.U., O'Day, S.J., Ascierto, P.A., Salama, A.K.S., Margolin, K.A., Loquai, C., Eigentler, T.K., Gangadhar, T.C., Carlino, M.S., Agarwala, S.S., Moschos, S.J., Sosman, J.A., Goldinger, S.M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J.M., Wolchok, J.D., Eggermont, A., Li, X.N., Zhou, W., Zernhelt, A.M., Lis, J., Ebbinghaus, S., Kang, S.P., Daud, A., Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16 (2015), 908–918.
53. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., Ribas, A., Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372 (2015), 2521–2532.
54. Schachter, J., Ribas, A., Long, G.V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T.M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N., Robert, C., Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390 (2017), 1853–1862.
55. Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C.D., Ahn, M.-J., Majem, M., Fidler, M.J., de Castro, G., Garrido, M., Lubiniecki, G.M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E.B., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
56. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R., KEYNOTE-024 Investigators, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
57. Chen, R., Zinzani, P.L., Fanale, M.A., Armand, P., Johnson, N.A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T.P., Tomita, A., von Tresckow, B., Shipp, M.A., Zhang, Y., Ricart, A.D., Balakumaran, A., Moskowitz, C.H., KEYNOTE-087, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35 (2017), 2125–2132.
58. Chow, L.Q.M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J.P., Burtness, B., Lee, S.-H., Keam, B., Kang, H., Muro, K., Weiss, J., Geva, R., Lin, C.-C., Chung, H.C., Meister, A., Dolled-Filhart, M., Pathiraja, K., Cheng, J.D., Seiwert, T.Y., Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol. 34 (2016), 3838–3845.
59. Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F., KEYNOTE-045 Investigators, Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376 (2017), 1015–1026.
60. Fuchs, C.S., Doi, T., Jang, R.W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S.I., Shah, M.A., Metges, J.-P., Garrido, M., Golan, T., Mandala, M., Wainberg, Z.A., Catenacci, D.V., Ohtsu, A., Shitara, K., Geva, R., Bleeker, J., Ko, A.H., Ku, G., Philip, P., Enzinger, P.C., Bang, Y.-J., Levitan, D., Wang, J., Rosales, M., Dalal, R.P., Yoon, H.H., Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol., 4, 2018, e180013.
61. Prasad, V., Kaestner, V., Mailankody, S., Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 4 (2018), 157–158.
62. Powles, T., Durán, I., van der Heijden, M.S., Loriot, Y., Vogelzang, N.J., De Giorgi, U., Oudard, S., Retz, M.M., Castellano, D., Bamias, A., Fléchon, A., Gravis, G., Hussain, S., Takano, T., Leng, N., Kadel, E.E., Banchereau, R., Hegde, P.S., Mariathasan, S., Cui, N., Shen, X., Derleth, C.L., Green, M.C., Ravaud, A., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391 (2018), 748–757.
63. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S.M., Hida, T., Kowalski, D.M., Dols, M.C., Cortinovis, D.L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O.A., De Marinis, F., Turna, H., Lee, J.-S., Ballinger, M., Kowanetz, M., He, P., Chen, D.S., Sandler, A., Gandara, D.R., OAK Study Group, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
64. Patel, M.R., Ellerton, J., Infante, J.R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C.D., Dirix, L., Lee, K.-W., Taylor, M., Schöffski, P., Wang, D., Ravaud, A., Gelb, A.B., Xiong, J., Rosen, G., Gulley, J.L., Apolo, A.B., Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 19 (2018), 51–64.
65. Kaufman, H.L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S.P., Shih, K.C., Lebbé, C., Linette, G.P., Milella, M., Brownell, I., Lewis, K.D., Lorch, J.H., Chin, K., Mahnke, L., von Heydebreck, A., Cuillerot, J.-M., Nghiem, P., Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17 (2016), 1374–1385.
66. Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K.H., de Wit, M., Cho, B.C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.C., Karapetis, C.S., Hiret, S., Ostoros, G., Kubota, K., Gray, J.E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P.A., Özgüroğlu, M., Investigators, PACIFIC, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N. Engl. J. Med. 377 (2017), 1919–1929.
67. Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S., Larkin, J., Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377 (2017), 1345–1356.
68. Motzer, R.J., Tannir, N.M., McDermott, D.F., Arén Frontera, O., Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B., CheckMate 214 Investigators, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378 (2018), 1277–1290.
69. Hellmann, M.D., Rizvi, N.A., Goldman, J.W., Gettinger, S.N., Borghaei, H., Brahmer, J.R., Ready, N.E., Gerber, D.E., Chow, L.Q., Juergens, R.A., Shepherd, F.A., Laurie, S.A., Geese, W.J., Agrawal, S., Young, T.C., Li, X., Antonia, S.J., Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 18 (2017), 31–41.
70. Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., Jäger, D., Pietanza, M.C., Le, D.T., de Braud, F., Morse, M.A., Ascierto, P.A., Horn, L., Amin, A., Pillai, R.N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P., Harbison, C.T., Lin, C.S., Christensen, O., Calvo, E., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (2016), 883–895.
71. Long, G.V., Atkinson, V., Cebon, J.S., Jameson, M.B., Fitzharris, B.M., McNeil, C.M., Hill, A.G., Ribas, A., Atkins, M.B., Thompson, J.A., Hwu, W.J., Hodi, F.S., Menzies, A.M., Guminski, A.D., Kefford, R., Kong, B.Y., Tamjid, B., Srivastava, A., Lomax, A.J., Islam, M., Shu, X., Ebbinghaus, S., Ibrahim, N., Carlino, M.S., Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 18 (2017), 1202–1210.
72. Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J.J., Rizvi, N.A., Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17 (2016), 299–308.
73. Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., Chandra, A.B., Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol., 8, 2017, 49.
74. Puzanov, I., Diab, A., Abdallah, K., Bingham, C.O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M.E., LeBoeuf, N.R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A.W., Skondra, D., Suarez-Almazor, M.E., Wang, Y., Wiley, K., Kaufman, H.L., Ernstoff, M.S., Society for Immunotherapy of Cancer Toxicity Management Working Group, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer, 5, 2017, 95.
75. El Osta, B., Hu, F., Sadek, R., Chintalapally, R., Tang, S.-C., Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit. Rev. Oncol. Hematol. 119 (2017), 1–12.
76. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P.F., Hill, A., Wagstaff, J., Carlino, M.S., Haanen, J.B., Maio, M., Marquez-Rodas, I., McArthur, G.A., Ascierto, P.A., Long, G.V., Callahan, M.K., Postow, M.A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L.M., Horak, C., Hodi, F.S., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
77. Nishijima, T.F., Shachar, S.S., Nyrop, K.A., Muss, H.B., Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 22 (2017), 470–479.
78. Man, J., Ritchie, G., Links, M., Lord, S., Lee, C.K., Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis. Asia Pac. J. Clin. Oncol., 2018, 10.1111/ajco.12838 (Epub ahead of print).
79. Pitt, J.M., Vétizou, M., Daillère, R., Roberti, M.P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I.G., Chamaillard, M., Kroemer, G., Zitvogel, L., Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44 (2016), 1255–1269.
80. Ji, R.R., Chasalow, S.D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N.O., Jackson, J.R., Shahabi, V., An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61 (2012), 1019–1031.
81. Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M.J.P., van der Burg, S., Kapiteijn, E., Michielin, O., Romano, E., Linnemann, C., Speiser, D., Blank, C., Haanen, J.B., Schumacher, T.N., Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med., 6, 2014, 254ra128.
82. Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D.R., Albright, A., Cheng, J.D., Kang, S.P., Shankaran, V., Piha-Paul, S.A., Yearley, J., Seiwert, T.Y., Ribas, A., McClanahan, T.K., IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127 (2017), 2930–2940.
83. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A.N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A.J., Grogan, T.R., Mateus, C., Tomasic, G., Glaspy, J.A., Emerson, R.O., Robins, H., Pierce, R.H., Elashoff, D.A., Robert, C., Ribas, A., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
84. Hargadon, K.M., Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma. Front. Immunol., 8, 2017, 1594.
85. Gibney, G.T., Weiner, L.M., Atkins, M.B., Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17 (2016), e542–e551.
86. Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M.D., Algazi, A.P., Pampaloni, M.H., Lobach, I.V., Hwang, J., Pierce, R.H., Gratz, I.K., Krummel, M.F., Rosenblum, M.D., Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J. Clin. Invest. 126 (2016), 3447–3452.
87. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
88. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., Merghoub, T., Wolchok, J.D., Schumacher, T.N., Chan, T.A., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
89. McGranahan, N., Furness, A.J.S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., Watkins, T.B.K., Shafi, S., Murugaesu, N., Mitter, R., Akarca, A.U., Linares, J., Marafioti, T., Henry, J.Y., Van Allen, E.M., Miao, D., Schilling, B., Schadendorf, D., Garraway, L.A., Makarov, V., Rizvi, N.A., Snyder, A., Hellmann, M.D., Merghoub, T., Wolchok, J.D., Shukla, S.A., Wu, C.J., Peggs, K.S., Chan, T.A., Hadrup, S.R., Quezada, S.A., Swanton, C., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
90. Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., Vaysse, T., Marthey, L., Eggermont, A., Asvatourian, V., Lanoy, E., Mateus, C., Robert, C., Carbonnel, F., Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28 (2017), 1368–1379.
91. Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P.M., Alou, M.T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., Ferrere, G., Clémenson, C., Mezquita, L., Masip, J.R., Naltet, C., Brosseau, S., Kaderbhai, C., Richard, C., Rizvi, H., Levenez, F., Galleron, N., Quinquis, B., Pons, N., Ryffel, B., Minard-Colin, V., Gonin, P., Soria, J.C., Deutsch, E., Loriot, Y., Ghiringhelli, F., Zalcman, G., Goldwasser, F., Escudier, B., Hellmann, M.D., Eggermont, A., Raoult, D., Albiges, L., Kroemer, G., Zitvogel, L., Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359 (2018), 91–97.
92. Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., Ahmed, R., Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion. J. Virol. 90 (2016), 8934–8946.
93. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., Barnitz, R.A., Bartman, C., Bengsch, B., Huang, A.C., Schenkel, J.M., Vahedi, G., Haining, W.N., Berger, S.L., Wherry, E.J., Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
94. Blackburn, S.D., Shin, H., Freeman, G.J., Wherry, E.J., Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade. Proc. Natl. Acad. Sci. 105 (2008), 15016–15021.
95. Chen, P.L., Roh, W., Reuben, A., Cooper, Z.A., Spencer, C.N., Prieto, P.A., Miller, J.P., Bassett, R.L., Gopalakrishnan, V., Wani, K., De Macedo, M.P., Austin-Breneman, J.L., Jiang, H., Chang, Q., Reddy, S.M., Chen, W.-S., Tetzlaff, M.T., Broaddus, R.J., Davies, M.A., Gershenwald, J.E., Haydu, L., Lazar, A.J., Patel, S.P., Hwu, P., Hwu, W.J., Diab, A., Glitza, I.C., Woodman, S.E., Vence, L.M., Wistuba, I.I., Amaria, R.N., Kwong, L.N., Prieto, V., Davis, R.E., Ma, W., Overwijk, W.W., Sharpe, A.H., Hu, J., Futreal, P.A., Blando, J., Sharma, P., Allison, J.P., Chin, L., Wargo, J.A., Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6 (2016), 827–837.
96. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., Chen, P.-L., Hwu, P., Allison, J.P., Futreal, A., Wargo, J.A., Sharma, P., Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404.e9.
97. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., Saco, J., Homet Moreno, B., Mezzadra, R., Chmielowski, B., Ruchalski, K., Shintaku, I.P., Sanchez, P.J., Puig-Saus, C., Cherry, G., Seja, E., Kong, X., Pang, J., Berent-Maoz, B., Comin-Anduix, B., Graeber, T.G., Tumeh, P.C., Schumacher, T.N.M., Lo, R.S., Ribas, A., Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.
98. Munn, D.H., Bronte, V., Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 (2016), 1–6.
99. Hargadon, K., Dysregulation of TGFβ1 activity in cancer and its influence on the quality of anti-tumor immunity. J. Clin. Med., 5, 2016, E76.
100. Torphy, R., Schulick, R., Zhu, Y., Newly emerging immune checkpoints: promises for future cancer therapy. Int. J. Mol. Sci., 18, 2017, E2642.